Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Alisertib (Primary) ; Pazopanib
- Indications Breast cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Thoracic neoplasms; Urogenital cancer
- Focus Adverse reactions
- 18 Apr 2017 Status changed from active, no longer recruiting to completed.
- 18 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
- 18 Nov 2016 Planned primary completion date changed from 1 May 2016 to 1 Mar 2017.